Agios' Supplemental New Drug Application for Its Thalassemia Treatment Gets FDA Nod

Seeking AlphaJan 8 08:30 ET

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BusinesswireJan 8 08:00 ET

Agios Pharmaceuticals Says FDA Accepted SNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia

BenzingaJan 8 07:04 ET

Express News | Agios Pharmaceuticals Inc - Pdufa Goal Date for Pyrukynd Snda Is September 7, 2025

ReutersJan 8 07:00 ET

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (Mitapivat) in Adult Patients With Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

GlobeNewswireJan 8 07:00 ET

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55

Moomoo NewsJan 7 07:36 ET · Ratings